<- Go Home
Frazier Lifesciences Acquisition Corporation
As of November 22, 2022, Frazier Lifesciences Acquisition Corporation was acquired by NewAmsterdam Pharma B.V., in a reverse merger transaction. Frazier Lifesciences Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or related business combination with one or more businesses or entities in the biotechnology sector. The company was incorporated in 2020 and is based in Seattle, Washington.
Market Cap
$166.9M
Volume
32.8K
Cash and Equivalents
$375.5K
EBITDA
N/A
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
N/A
Profit Margin
N/A
52 Week High
$10.83
52 Week Low
$7.52
Dividend
N/A
Price / Book Value
-14.30
Price / Earnings
-45.86
Price / Tangible Book Value
-14.30
Enterprise Value
$166.5M
Enterprise Value / EBITDA
N/A
Operating Income
-$5.1M
Return on Equity
N/A
Return on Assets
N/A
Cash and Short Term Investments
$375.5K
Debt
N/A
Equity
-$11.7M
Revenue
N/A
Unlevered FCF
N/A
Sector
Capital Markets
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium